AR075977A1 - Procedimiento de sintesis de ivabradina y/o su derivado amino hidrogenado y de sus sales de adicion a un acido farmaceuticamente aceptable e intermediarios de sintesis. - Google Patents
Procedimiento de sintesis de ivabradina y/o su derivado amino hidrogenado y de sus sales de adicion a un acido farmaceuticamente aceptable e intermediarios de sintesis.Info
- Publication number
- AR075977A1 AR075977A1 ARP100101002A ARP100101002A AR075977A1 AR 075977 A1 AR075977 A1 AR 075977A1 AR P100101002 A ARP100101002 A AR P100101002A AR P100101002 A ARP100101002 A AR P100101002A AR 075977 A1 AR075977 A1 AR 075977A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- compound
- pharmaceutically acceptable
- addition salts
- ivabradine
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title abstract 5
- 238000003786 synthesis reaction Methods 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 4
- 239000002253 acid Substances 0.000 title abstract 3
- ACRHBAYQBXXRTO-OAQYLSRUSA-N ivabradine Chemical compound C1CC2=CC(OC)=C(OC)C=C2CC(=O)N1CCCN(C)C[C@H]1CC2=C1C=C(OC)C(OC)=C2 ACRHBAYQBXXRTO-OAQYLSRUSA-N 0.000 title abstract 3
- 229960003825 ivabradine Drugs 0.000 title abstract 3
- -1 HYDROGEN AMINO DERIVATIVE Chemical class 0.000 title abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 title 1
- 239000001257 hydrogen Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 10
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 abstract 3
- 150000004678 hydrides Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 abstract 2
- 238000006243 chemical reaction Methods 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 150000004677 hydrates Chemical class 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 239000012458 free base Substances 0.000 abstract 1
- 235000011087 fumaric acid Nutrition 0.000 abstract 1
- 150000002238 fumaric acids Chemical class 0.000 abstract 1
- 229910052747 lanthanoid Inorganic materials 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 abstract 1
- 229910052723 transition metal Inorganic materials 0.000 abstract 1
- 150000003624 transition metals Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Reivindicacion 1: Procedimiento de síntesis del compuesto de formula (7), en forma racémica u opticamente activa en la que R representa un átomo de hidrogeno o un grupo metilo, caracterizado porque el compuesto de formula (8) se hace reaccionar con el compuesto de formula (9) en forma racémica u opticamente activa, en forma de base libre o de sal en la que R es tal como se ha definido anteriormente, en presencia de una sal de metal de transicion o de lantánido, en un disolvente, para dar lugar al compuesto de formula (10), forma racémica u opticamente activa que se transforma en compuesto de formula (7) por accion de un agente donador de hidruro. Reivindicacion 3: Procedimiento de síntesis segun la reivindicacion 2, caracterizado porque R representa un átomo de hidrogeno y porque el producto de la reaccion del compuesto de formula (10) con el agente donador de hidruro es el compuesto de formula (11), caso particular de los compuestos de formula (7), que puede N-metilarse para dar lugar a la ivabradina de formula (1), que puede transformarse opcionalmente en sus sales de adicion a un ácido farmacéuticamente aceptable, elegido entre los ácidos clorhídrico, bromhídrico, sulfurico, fosforico, acético, trifluoroacético, láctico, piruvico, malonico, succínico, glutárico, fumárico, tártrico, maleico, cítrico, ascorbico, oxálico, metanosulfonico, bencenosulfonico y canforico, y en sus hidratos. Reivindicacion 4: Procedimiento de síntesis segun la reivindicacion 2, caracterizado porque R representa un grupo metilo y porque el producto de la reaccion del compuesto de formula (10) con el agente donador de hidruro es la ivabradina de formula (1), caso particular de los compuestos de formula (7), que puede transformarse opcionalmente en sus sales de adicion a un ácido farmacéuticamente aceptable, elegido entre los ácidos clorhídrico, bromhídrico, sulfurico, fosforico, acético, trifluoroacético, láctico, piruvico, malonico, succínico, glutárico, fumárico, tártrico, maleico, cítrico, ascorbico, oxálico, metanosulfonico, bencenosulfonico y canforico, y en sus hidratos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0901555A FR2943667B1 (fr) | 2009-03-31 | 2009-03-31 | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR075977A1 true AR075977A1 (es) | 2011-05-11 |
Family
ID=40984744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101002A AR075977A1 (es) | 2009-03-31 | 2010-03-29 | Procedimiento de sintesis de ivabradina y/o su derivado amino hidrogenado y de sus sales de adicion a un acido farmaceuticamente aceptable e intermediarios de sintesis. |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US8101747B2 (es) |
| EP (1) | EP2241554B1 (es) |
| JP (1) | JP5107382B2 (es) |
| KR (1) | KR101166630B1 (es) |
| CN (2) | CN102603634B (es) |
| AR (1) | AR075977A1 (es) |
| AT (1) | ATE523494T1 (es) |
| AU (1) | AU2010201058B2 (es) |
| BR (1) | BRPI1000735A2 (es) |
| CA (1) | CA2697562C (es) |
| CL (1) | CL2010000254A1 (es) |
| CY (1) | CY1112136T1 (es) |
| DK (1) | DK2241554T3 (es) |
| EA (1) | EA016335B1 (es) |
| ES (1) | ES2373369T3 (es) |
| FR (1) | FR2943667B1 (es) |
| GE (1) | GEP20125460B (es) |
| HR (1) | HRP20110915T1 (es) |
| JO (1) | JO2782B1 (es) |
| MA (1) | MA31745B1 (es) |
| ME (1) | ME00987B (es) |
| MX (1) | MX2010003184A (es) |
| MY (1) | MY145611A (es) |
| NZ (1) | NZ584309A (es) |
| PE (1) | PE20100714A1 (es) |
| PL (1) | PL2241554T3 (es) |
| PT (1) | PT2241554E (es) |
| RS (1) | RS51962B (es) |
| SA (1) | SA110310240B1 (es) |
| SG (1) | SG165254A1 (es) |
| SI (1) | SI2241554T1 (es) |
| TW (1) | TWI419879B (es) |
| UA (1) | UA102232C2 (es) |
| UY (1) | UY32500A (es) |
| WO (1) | WO2010112704A1 (es) |
| ZA (1) | ZA201002121B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2473544C2 (ru) * | 2007-05-30 | 2013-01-27 | Инд-Свифт Лабораториз Лимитед | Способ получения ивабрадина гидрохлорида и его полиморфных модификаций |
| CN103848789B (zh) * | 2012-11-29 | 2016-05-18 | 江苏恒瑞医药股份有限公司 | 一种伊伐布雷定的制备方法 |
| CN103724266B (zh) * | 2014-01-20 | 2018-12-04 | 山东诚创医药技术开发有限公司 | 去甲伊伐布雷定盐及其制备方法和应用 |
| EP3101010A1 (en) | 2015-06-03 | 2016-12-07 | Urquima S.A. | New method for the preparation of highly pure ivabradine base and salts thereof |
| CN108530359A (zh) * | 2017-03-01 | 2018-09-14 | 浙江京新药业股份有限公司 | 一种伊伐布雷定杂质的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1140049A (en) * | 1965-04-02 | 1969-01-15 | Alphachimie S A | N-substituted tetrahydrobenzazepines |
| US3743731A (en) * | 1971-03-16 | 1973-07-03 | Schering Corp | Substituted benzazepines for producing skeletal muscle relaxation |
| DE3119874A1 (de) * | 1981-05-19 | 1982-12-09 | Dr. Karl Thomae Gmbh, 7950 Biberach | "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel" |
| FR2681862B1 (fr) * | 1991-09-27 | 1993-11-12 | Adir Cie | Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent. |
| FR2868777B1 (fr) * | 2004-04-13 | 2006-05-26 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
| FR2870537A1 (fr) * | 2004-05-19 | 2005-11-25 | Servier Lab | Nouveau procede de synthese du (1s)-4,5-dimethoxy-1-(methyl aminomethyl-)-benzocyclobutane et de ses sels d'addition, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
| EP2460797A3 (en) * | 2006-11-30 | 2012-12-05 | Cadila Healthcare Limited | Process for preparation of ivabradine hydrochloride |
| CN101284813B (zh) * | 2007-04-12 | 2012-08-15 | 上海优拓医药科技有限公司 | 伊伐布雷定的制备方法 |
| RU2473544C2 (ru) | 2007-05-30 | 2013-01-27 | Инд-Свифт Лабораториз Лимитед | Способ получения ивабрадина гидрохлорида и его полиморфных модификаций |
-
2009
- 2009-03-31 FR FR0901555A patent/FR2943667B1/fr not_active Expired - Fee Related
- 2009-03-31 ME MEP-2010-55A patent/ME00987B/me unknown
-
2010
- 2010-03-16 PE PE2010000154A patent/PE20100714A1/es not_active Application Discontinuation
- 2010-03-16 SG SG201001800-0A patent/SG165254A1/en unknown
- 2010-03-17 MY MYPI2010001176A patent/MY145611A/en unknown
- 2010-03-17 UY UY0001032500A patent/UY32500A/es not_active Application Discontinuation
- 2010-03-18 AU AU2010201058A patent/AU2010201058B2/en not_active Ceased
- 2010-03-18 MA MA32704A patent/MA31745B1/fr unknown
- 2010-03-22 CL CL2010000254A patent/CL2010000254A1/es unknown
- 2010-03-23 MX MX2010003184A patent/MX2010003184A/es active IP Right Grant
- 2010-03-24 CA CA2697562A patent/CA2697562C/fr not_active Expired - Fee Related
- 2010-03-25 ZA ZA2010/02121A patent/ZA201002121B/en unknown
- 2010-03-29 UA UAA201003588A patent/UA102232C2/uk unknown
- 2010-03-29 SA SA110310240A patent/SA110310240B1/ar unknown
- 2010-03-29 AR ARP100101002A patent/AR075977A1/es not_active Application Discontinuation
- 2010-03-29 US US12/798,042 patent/US8101747B2/en not_active Expired - Fee Related
- 2010-03-29 GE GEAP201011741A patent/GEP20125460B/en unknown
- 2010-03-29 TW TW099109451A patent/TWI419879B/zh not_active IP Right Cessation
- 2010-03-29 NZ NZ584309A patent/NZ584309A/en not_active IP Right Cessation
- 2010-03-30 AT AT10290166T patent/ATE523494T1/de active
- 2010-03-30 WO PCT/FR2010/000268 patent/WO2010112704A1/fr not_active Ceased
- 2010-03-30 DK DK10290166.7T patent/DK2241554T3/da active
- 2010-03-30 EP EP10290166A patent/EP2241554B1/fr active Active
- 2010-03-30 SI SI201030013T patent/SI2241554T1/sl unknown
- 2010-03-30 ES ES10290166T patent/ES2373369T3/es active Active
- 2010-03-30 BR BRPI1000735-0A patent/BRPI1000735A2/pt not_active Application Discontinuation
- 2010-03-30 JP JP2010076768A patent/JP5107382B2/ja active Active
- 2010-03-30 PL PL10290166T patent/PL2241554T3/pl unknown
- 2010-03-30 PT PT10290166T patent/PT2241554E/pt unknown
- 2010-03-30 RS RS20110479A patent/RS51962B/sr unknown
- 2010-03-30 EA EA201000397A patent/EA016335B1/ru not_active IP Right Cessation
- 2010-03-31 CN CN201210034916.XA patent/CN102603634B/zh not_active Expired - Fee Related
- 2010-03-31 JO JO2010104A patent/JO2782B1/en active
- 2010-03-31 KR KR1020100029258A patent/KR101166630B1/ko not_active Expired - Fee Related
- 2010-03-31 CN CN2010101547205A patent/CN101851205B/zh not_active Expired - Fee Related
-
2011
- 2011-12-05 CY CY20111101203T patent/CY1112136T1/el unknown
- 2011-12-06 HR HR20110915T patent/HRP20110915T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR075978A1 (es) | Procedimiento de sintesis de ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable | |
| AR074845A1 (es) | Procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable | |
| AR075227A1 (es) | Procedimiento de sintesis de ivabradina y sus sales de adicion de acidos farmaceuticamente aceptables. | |
| CO6290677A2 (es) | Procesos e intermediarios para la preparación de derivados de acido 5-bifenil-4-il-2-metilpentanoico. | |
| AR075977A1 (es) | Procedimiento de sintesis de ivabradina y/o su derivado amino hidrogenado y de sus sales de adicion a un acido farmaceuticamente aceptable e intermediarios de sintesis. | |
| NZ598291A (en) | Quinoline derivative-containing pharmaceutical composition | |
| MX2009006207A (es) | Proceso para la obtencion del acido 1-(2-etil-butil)-ciclohexanoca rboxilico. | |
| CL2008002654A1 (es) | Compuestos derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, bloqueadores de los canales hcn; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cardiopatias isquemicas, insuficiencias cardiacas tanto sistolicas como diastolicas, entre otras. | |
| MY150280A (en) | Process of preparing derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid | |
| UA101712C2 (ru) | Способ производства производных замещенной метоксиметилпиридин-2,3-дикарбоновой кислоты | |
| NZ597638A (en) | 5-fluoro-2-oxopyrimidine- 1(2h)-carboxylate derivatives | |
| GEP20125407B (en) | New process for the synthesis of 7,8-dimethoxy-1,3-dihydro-2h-3- benzazepin-2-one, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | |
| AR077925A1 (es) | Sintesis selectiva de pirimidinas funcionalizadas | |
| AR078179A1 (es) | Procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable | |
| AR075915A1 (es) | Proceso para la obtencion de derivados de acido propionico | |
| CO6341560A2 (es) | Proceso para la preparacion de derivados de pirimidina sustituidos. | |
| MX2012000685A (es) | Compuesto de 3-fenoximetilpirrolidina. | |
| MX2010009876A (es) | Nuevo proceso para la preparacion de derivados de acido ciclohexanocarboxilico por medio del derivado de ciclohexanocarboxamida correspondiente. | |
| MX2010009926A (es) | Nuevo proceso para la preparacion de derivados de acido ciclohexancarboxilico. | |
| AR080178A1 (es) | Procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable | |
| AR085344A1 (es) | Proceso de sintesis de ivabradina e intermediarios de dicha sintesis | |
| RU2012142338A (ru) | Способ получения 2-(циклогексилметил)-n-{2-[(2s)-1-метилпирролидин-2-ил]-этил}-1,2,3,4-тетрагидроизохинолин-7-сульфонамида | |
| NZ599147A (en) | Processes for the preparation of 2-(1-phenylethyl) isoindolin-1-one compounds | |
| PE20131097A1 (es) | Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable | |
| MD4392B1 (ro) | Procedeu de sinteză a (2E)-3-(3,4-dimetoxifenil)prop-2-ennitrilului şi aplicarea acestuia în sinteza ivabradinei şi a sărurilor sale de adiţie cu un acid acceptabil farmaceutic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |